"These companies each have a legacy of more than 100 years of advancing the world of health and supporting those on the frontlines of health care. "Today is a historic day for BD as we welcome Bard and its 16,000 associates to BD," said Vincent A. Additionally, Bard's strong product portfolio and innovation pipeline will increase BD's opportunities in fast-growing clinical areas, and the combination will enhance growth opportunities for the combined company in non-U.S. The transaction builds on BD's leadership in medication management and infection prevention with an expanded offering of solutions across the care continuum. The combined company is uniquely positioned to improve both the treatment of disease for patients and the process of care for health care providers. (NYSE: BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue. 29, 2017 / PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. Policies, Guidelines and Statements CenterįRANKLIN LAKES, N.J., Dec.ESG (Environmental, Social, and Governance).Vascular Access and Medication Delivery.Patient Care Support Across the Continuum.COVID-19 Tests and Vaccine Preparedness.
BD Original Equipment Manufacturing (OEM).
0 kommentar(er)
